10 July 2024

**Scancell Holdings plc**

(“Scancell” or the “Company”)

**Appointment of Dr Florian Reinaud to the Board of Directors**

*Dr Reinaud brings over 20 years of executive, non-executive and financial experience from the healthcare sector*

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that Dr Florian Reinaud, of Redmile Group, LLC (“Redmile”) has been appointed as a Non-Executive Director to Scancell’s Board of Directors (the “Board”).

Florian is a highly accomplished life sciences professional who brings over 20 years of leadership and investment experience across established pharmaceutical companies, start-ups and healthcare investment organisations. He is currently on the investment team at Redmile, an investment firm that focuses on the healthcare sector. Florian began his career as a medical doctor in the NHS before moving to Schroders Salomon Smith Barney, Citigroup’s European investment banking arm, working as an equity analyst covering the pan-European medtech and healthcare services. He then transitioned to the healthcare team at Apax Partners in Paris, advising on and executing venture and late-stage investments.

Following his time at Apax, Partners, Florian became the first CFO of Paris-based DBV technologies, a biopharmaceutical specialising in allergy diagnosis and treatment, and then went on to serve as Partner at CDC Innovation Capital, a French venture capital firm focused on investments in healthcare services, for six years. He later co-founded and served as CEO of Concilio, a medical concierge service, for six years, before joining Redmile.

Florian holds a BA (hons) in Physiology from Oxford University, as well as a medical degree from Imperial College London School of Medicine.

**Dr Jean-Michel Cosséry, Non-Executive Chairman of Scancell said:** *“On behalf of the Board, I am pleased to welcome Florian to Scancell, where he will represent one of the Company’s key investors. His broad biopharmaceutical industry and financial experience, coupled with his strong relationships with the investment community and first-hand experience in the medical field, will be invaluable as we continue to advance our lead assets through later stage clinical development, and I am confident he will add significant value to the Company.”*

**Additional Information**

In accordance with the AIM Rules, the following information required to be disclosed in relation to Florian Reinaud is set out below. Other than this information, there is no further information required to be disclosed under paragraph (g) of Schedule Two of the AIM Rules.

**Full name and age:** Florian Reinaud, aged 50

|  |  |
| --- | --- |
| **Current Directorships** | **Previous Directorships (last 5 years)** |
| Sensome SAS  Sensorion SA  Hansa Biopharma AB | Concilio |

Dr Florian Reinaud does not have an interest in any ordinary shares or share options in Scancell.

|  |  |
| --- | --- |
| **For further information, please contact:** |  |
| **Scancell Holdings plc** | +44 (0) 20 3709 5700 |
| Professor Lindy Durrant, CEO  Dr Jean-Michel Cosséry, Non-Executive Chairman |  |
| **Panmure Liberum Limited** (Nominated Advisor and Joint Broker) | +44 (0) 20 7886 2500 |
| Emma Earl, Freddy Crossley, Will Goode, Mark Rogers (Corporate Finance) |  |
| Rupert Dearden (Corporate Broking) |  |
| **WG Partners LLP (Joint Broker)** | +44 (0) 20 3705 9330 |
| David Wilson/Claes Spang/Satheesh Nadarajah/Erland Sternby |  |

**About Scancell**

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company’s unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody® ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab® ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab® ).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>